One-Year EVOLVE Trial Clinical Results Confirm Comparable Safety And Effectiveness Data Of The Boston … - Yahoo Finance

NATICK, Mass., May 15, 2012 /PRNewswire/ -- Boston Scientific Corporation (BSX) announces that the SYNERGY™ Everolimus-Eluting Bioabsorbable Polymer-Coated Platinum Chromium Coronary Stent System demonstrated non-inferior results in treating ...

A Few Thoughts On The actual Near Future For Doxorubicin - 1UP.COM

TKI to the other, either with sorafenib followed by sunitinib SoSu or sunitinib followed by sorafenib SuSo. Everolimus was associatedwith a median PFS of . months in the in general inhabitants versus . months for placebo hazard ratio HR . self confidence ...

One-Year EVOLVE Trial Clinical Results Confirm Comparable Safety And ...  - CNBC

NATICK, Mass., May 15, 2012 /PRNewswire via COMTEX/ -- Boston Scientific Corporation (NYSE: BSX) announces that the SYNERGY(TM) Everolimus-Eluting Bioabsorbable Polymer-Coated Platinum Chromium Coronary Stent System demonstrated non-inferior results in ...

Research and Markets: Afinitor (Pancreatic Cancer) - Analysis and Forecasts to 2020 - CNBC

everolimus, Pancreatic cancer, Sales forecast, targeted therapy , phase III, phase 3, pipeline, GVAX, HyperAcute Pancreas, Irinotecan, Sutent, GV1001, Afinitor, Avastin, AMG479, Abraxane, Masitinib, Gemzar, Nexavar, S-1, Tarceva, Certican, Novartis For ...

Novartis to probe Indian drug approval allegations - MoneyControl.com

In the case of eleven drugs, including Novartis' Everolimus and Aliskiren, it found that "mandatory" phase-III trials - the final stage of testing before a drug is approved - had not been conducted as required. Specifically, in the case of ...

Abbott (ABT) XIENCE Stent Systems Get CE Mark in Europe - StreetInsider.com

Abbott (NYSE: ABT) reports that the XIENCE PRIME and the XIENCE V Everolimus Eluting Coronary Stent Systems have received CE Mark in Europe for the use of dual anti-platelet therapy (DAPT) for at least three months after stent implantation in patients with ...

Boston Scientific (BSX) Reports Encouraging Data from PROMUS Element Study; - StreetInsider.com

Boston Scientific Corporation (NYSE: BSX) announces two-year results from the PLATINUM Small Vessel study, demonstrating excellent safety and effectiveness outcomes for the 2.25 mm PROMUS Element Everolimus-Eluting Platinum Chromium (PtCr) Stent System in ...

PROMUS Element™ Stent Demonstrates Excellent Long-Term Safety and Effectiveness in PLATINUM Small Vessel Study - Yahoo Finance

May 18, 2012 /PRNewswire/ -- Boston Scientific Corporation (BSX) announces two-year results from the PLATINUM Small Vessel study, demonstrating excellent safety and effectiveness outcomes for the 2.25 mm PROMUS Element™ Everolimus-Eluting Platinum ...

Good morning - American Cancer Society

I hope you all are doing fine. I have been having up days and down days. I go to see my oncologist tomorrow and I am sure she is going to bring up the Everolimus trial to me again. At the risk of repeating myself (guessing I just need a little more ...